Nicole P. Lindsey

Nicole P. Lindsey

Auto-generated profile, based on publicly available information

Nicole P. Lindsey

Arboviral Diseases Branch, Centers for Disease Control and Prevention, Fort Collins, Colorado

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2008 in Vaccine
Verified
Journal Article
Open access
NLNicole P. Lindsey
Nicole P. Lindsey
BSBetsy A. Schroeder
Betsy A. Schroeder
EMElaine R. Miller
Elaine R. Miller
MBM. Miles Braun
M. Miles Braun
AHAlison F. Hinckley
Alison F. Hinckley
EHEdward B. Hayes
Edward B. Hayes
Yellow fever (YF) vaccine has been used for prevention of YF since 1937 with over 500 million doses administered. However, rare reports of severe adverse events following vaccination have raised concerns about the vaccine's safety. We reviewed reports of adverse events following YF vaccination reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 2000 to 2006. We used estimates of age and sex distribution of administered doses obtained from a 2006 survey of authorized vaccine providers to calculate age- and sex-specific reporting rates of all serious adverse events (SAE), anaphylaxis, YF vaccine-associated neurotropic disease, and YF vaccine-associated viscerotropic disease. Reporting rates of SAEs were substantially higher in males and in persons aged > or =60 years. These findings reinforce the generally acceptable safety profile of YF vaccine, but highlight the importance of physician and traveler education regarding the risks and benefits of YF vaccination, particularly for travelers > or =60 years of age. Vaccination should be limited to persons traveling to areas where the risk of YF is expected to exceed the risk of serious adverse events after vaccination, or if not medically contraindicated, where national regulations require proof of vaccination to prevent introduction of YF.

1 May 2016 in Journal of Travel Medicine
Verified
Journal Article
Open access
PDF file
NLNicole P. Lindsey
Nicole P. Lindsey
IRIngrid B. Rabe
Ingrid B. Rabe
EMElaine R. Miller
Elaine R. Miller
MFMarc Fischer
Marc Fischer
JSJ. Erin Staples
J. Erin Staples
Background : Yellow fever (YF) vaccines have been available since the 1930s and are generally considered safe and effective. However, rare reports of serious adverse events (SAE) following vaccination have prompted the Advisory Committee for Immunization Practices to periodically expand the list of conditions considered contraindications and precautions to vaccination. Methods : We describe adverse events following YF vaccination reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 2007 through 2013 and calculate age- and sex-specific reporting rates of all SAE, anaphylaxis, YF vaccine-associated neurologic disease (YEL-AND) and YF vaccine-associated viscerotropic disease (YEL-AVD). Results : There were 938 adverse events following YF vaccination reported to VAERS from 2007 through 2013. Of these, 84 (9%) were classified as SAEs for a rate of 3.8 per 100 000 doses distributed. Reporting rates of SAEs increased with increasing age with a rate of 6.5 per 100 000 in persons aged 60–69 years and 10.3 for ≥70 years. The reporting rate for anaphylaxis was 1.3 per 100 000 doses distributed and was highest in persons ≤18 years (2.7 per 100 000). Reporting rates of YEL-AND and YEL-AVD were 0.8 and 0.3 per 100 000 doses distributed, respectively; both rates increased with increasing age. Conclusions : These findings reinforce the generally acceptable safety profile of YF vaccine, but highlight the importance of continued physician and traveller education regarding the risks and benefits of YF vaccination, particularly for older travellers.

2 April 2010
Verified
Journal Article
Closed access
NLNicole P Lindsey
Nicole P Lindsey
JSJ Erin Staples
J Erin Staples
JLJennifer A Lehman
Jennifer A Lehman
MFMarc Fischer
Marc Fischer

2 July 2012 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
NLNicole P. Lindsey
Nicole P. Lindsey
JSJ. Erin Staples
J. Erin Staples
JLJennifer A. Lehman
Jennifer A. Lehman
MFMarc Fischer
Marc Fischer
We conducted enhanced surveillance to identify medical risk factors for severe illness (i.e., hospitalization or death) and neuroinvasive disease (i.e., encephalitis or meningitis) among all West Nile virus disease cases reported from selected states from 2008 to 2010. Of the 1,090 case-patients included in the analysis, 708 (65%) case-patients were hospitalized, 641 (59%) case-patients had neuroinvasive disease, and 55 (5%) case-patients died. Chronic renal disease (adjusted odds ratio [aOR] = 4.1; 95% confidence interval [CI] = 1.4–12.1), history of cancer (aOR = 3.7; 95% CI = 1.8–7.5), history of alcohol abuse (aOR = 3.0; 95% CI = 1.3–6.7), diabetes (aOR = 2.2; 95% CI = 1.4–3.4), and hypertension (aOR = 1.5; 95% CI = 1.1–2.1) were independently associated with severe illness on multivariable analysis. Although the same medical conditions were independently associated with encephalitis, only hypertension was associated with meningitis. The only condition independently associated with death was immune suppression. Prevention messages should be targeted to persons with these conditions.

5 March 2021 in Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
EMEmily McDonald
Emily McDonald
SMSarabeth Mathis
Sarabeth Mathis
SMStacey W. Martin
Stacey W. Martin
JSJ. Erin Staples
J. Erin Staples
MFMarc Fischer
Marc Fischer
NLNicole P. Lindsey
Nicole P. Lindsey
This report describes surveillance data for West Nile virus during 2009-2018.

17 January 2020 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
NLNicole P. Lindsey
Nicole P. Lindsey
SMStacey W. Martin
Stacey W. Martin
JSJ. Erin Staples
J. Erin Staples
MFMarc Fischer
Marc Fischer
This summer’s record-breaking outbreak of Eastern equine encephalitis highlights the importance of cities and states ability to prepare for and respond to vectorborne disease threats.